Mitoxantrone (Teva®)

Common name: Mitoxantrone
Brand name: Teva®
 

What is Mitoxantrone?

Mitoxantrone is a chemotherapy drug used to treat advanced prostate cancer by interfering with the growth and reproduction of cancer cells. This therapy is used in combination with corticosteroids, such as prednisone or prednisolone.


How is Mitoxantrone administered?

Mitoxantrone is administered by injection.
 

What are possible side effects of this treatment?

Everyone responds differently to chemotherapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received mitoxantrone. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.

 
•    Bleeding / bruising
•    Diarrhea
•    Fatigue
•    Hair loss
•    Infection
•    Liver problems
•    Mouth sores
•    Nausea / vomiting
•    Pain, burning, redness, swelling at injection site
 
 

Is Mitoxantrone covered in my province or territory?

Provincial Coverage: Unknown    
    
Last Reviewed: July 2017

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More

Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More


Click here for news archive